Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
Dyslipidemia is a potent risk factor for the genesis and progression of cardiovascular disease (CVD), and both the concentration and type of low-density lipoproteins (LDL) augment this association. The small, dense LDL (sdLDL) subfraction is the subtype which is most strongly predictive of atheroscl...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/9/11/1579 |
| _version_ | 1797511122101731328 |
|---|---|
| author | Ali A. Rizvi Anca Pantea Stoian Andrej Janez Manfredi Rizzo |
| author_facet | Ali A. Rizvi Anca Pantea Stoian Andrej Janez Manfredi Rizzo |
| author_sort | Ali A. Rizvi |
| collection | DOAJ |
| description | Dyslipidemia is a potent risk factor for the genesis and progression of cardiovascular disease (CVD), and both the concentration and type of low-density lipoproteins (LDL) augment this association. The small, dense LDL (sdLDL) subfraction is the subtype which is most strongly predictive of atherosclerosis and cardiovascular events. In addition to the traditionally available lipid-lowering treatment options, certain novel therapies have been shown to favorably impact sdLDL, among them the antidiabetic class of agents known as glucagon-like peptide 1 receptor agonists (GLP1-RAs). These drugs seem to alter the pathophysiologic mechanisms responsible for the formation and accumulation of atherogenic lipoprotein particles, thus potentially reducing cardiovascular outcomes. They represent a uniquely targeted therapeutic approach to reduce cardiometabolic risk and warrant further study for their beneficial nonglycemic actions. |
| first_indexed | 2024-03-10T05:40:58Z |
| format | Article |
| id | doaj.art-239a0fd9ed42401d81fc6c024719ad16 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T05:40:58Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-239a0fd9ed42401d81fc6c024719ad162023-11-22T22:30:18ZengMDPI AGBiomedicines2227-90592021-10-01911157910.3390/biomedicines9111579Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical OptionsAli A. Rizvi0Anca Pantea Stoian1Andrej Janez2Manfredi Rizzo3Department of Medicine, University of Central Florida College of Medicine, Orlando, FL 32827, USADepartment of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine, 050474 Bucharest, RomaniaDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, SloveniaDivision of Endocrinology, Diabetes and Metabolism University of South Carolina School of Medicine Columbia, Columbia, SC 29209, USADyslipidemia is a potent risk factor for the genesis and progression of cardiovascular disease (CVD), and both the concentration and type of low-density lipoproteins (LDL) augment this association. The small, dense LDL (sdLDL) subfraction is the subtype which is most strongly predictive of atherosclerosis and cardiovascular events. In addition to the traditionally available lipid-lowering treatment options, certain novel therapies have been shown to favorably impact sdLDL, among them the antidiabetic class of agents known as glucagon-like peptide 1 receptor agonists (GLP1-RAs). These drugs seem to alter the pathophysiologic mechanisms responsible for the formation and accumulation of atherogenic lipoprotein particles, thus potentially reducing cardiovascular outcomes. They represent a uniquely targeted therapeutic approach to reduce cardiometabolic risk and warrant further study for their beneficial nonglycemic actions.https://www.mdpi.com/2227-9059/9/11/1579smalldense LDLpreventioncardiovascular risktherapydiabetes |
| spellingShingle | Ali A. Rizvi Anca Pantea Stoian Andrej Janez Manfredi Rizzo Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options Biomedicines small dense LDL prevention cardiovascular risk therapy diabetes |
| title | Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options |
| title_full | Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options |
| title_fullStr | Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options |
| title_full_unstemmed | Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options |
| title_short | Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options |
| title_sort | lipoproteins and cardiovascular disease an update on the clinical significance of atherogenic small dense ldl and new therapeutical options |
| topic | small dense LDL prevention cardiovascular risk therapy diabetes |
| url | https://www.mdpi.com/2227-9059/9/11/1579 |
| work_keys_str_mv | AT aliarizvi lipoproteinsandcardiovasculardiseaseanupdateontheclinicalsignificanceofatherogenicsmalldenseldlandnewtherapeuticaloptions AT ancapanteastoian lipoproteinsandcardiovasculardiseaseanupdateontheclinicalsignificanceofatherogenicsmalldenseldlandnewtherapeuticaloptions AT andrejjanez lipoproteinsandcardiovasculardiseaseanupdateontheclinicalsignificanceofatherogenicsmalldenseldlandnewtherapeuticaloptions AT manfredirizzo lipoproteinsandcardiovasculardiseaseanupdateontheclinicalsignificanceofatherogenicsmalldenseldlandnewtherapeuticaloptions |